CBD Nanoparticles Suppressed Liver Tumor Growth in New Study
- Cannabidiol (CBD) delivered via specially designed nanomicelles significantly inhibited liver tumor growth in mice, showing effectiveness comparable to the chemotherapy drug cyclophosphamide.
- The CBD/HA-SS-LA nanomicelles improved CBD’s water solubility by 367 times, effectively encapsulated 86% of the CBD, and released 70.2% of it in tumor-like conditions, targeting tumors specifically.
- Treated mice exhibited enhanced immune responses, with increased levels of tumor necrosis factor alpha and interleukin-2, suggesting the CBD formulation may also boost the immune system against tumors.
- While promising, these results are preclinical, and further research including human trials is necessary to confirm safety and effectiveness for liver cancer treatment in patients.
Cannabidiol (CBD) delivered through specially designed nanoparticles significantly inhibited liver tumor growth in mice, performing comparably to a commonly used chemotherapy drug, according to a study published in the Journal of Drug Delivery Science and Technology.
Researchers developed microscopic drug carriers designed to overcome one of the primary obstacles to using CBD therapeutically: its extremely poor solubility in water. The carriers, known as CBD/HA-SS-LA nanomicelles, were engineered to accumulate in tumors and release CBD in response to the acidic and chemically reductive conditions found within the tumor microenvironment.
Hepatocellular carcinoma is the most common form of primary liver cancer and remains difficult to treat because of its aggressive nature.
Laboratory testing showed that the nanomicelles increased CBD’s apparent water solubility by 367 times. They encapsulated approximately 86% of the CBD used and released 70.2% of the compound under conditions designed to simulate the environment inside a tumor.
Imaging performed in mice showed that the CBD-loaded nanomicelles accumulated more strongly in tumors and remained there longer than free CBD and nonresponsive delivery systems.
In mice implanted with H22 liver tumors, treatment with the nanomicelles produced “potent tumor growth inhibition” comparable to cyclophosphamide, a chemotherapy and immune-suppressing medication. The researchers also reported good biosafety during the experiment.
Treatment increased blood levels of tumor necrosis factor alpha and interleukin-2, two proteins involved in regulating immune responses. According to the researchers, this indicated that the CBD formulation may have strengthened the immune system’s response against the tumors in addition to delivering CBD more effectively.
“These findings suggest that pH/reduction-responsive HA-SS-LA nanomicelles provide a robust platform for efficient CBD delivery and targeted HCC therapy by modulating both solubility and immune microenvironments,” the researchers concluded.
The findings are preclinical and do not establish that CBD can treat liver cancer in humans. Further research, including human clinical trials, would be needed to determine the treatment’s safety and effectiveness in patients.